|Bid||0.0000 x 2200|
|Ask||0.0000 x 1300|
|Day's Range||1.6900 - 1.8400|
|52 Week Range||1.3800 - 3.3000|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Spherical Nucleic Acid technology shows promising results in phase 0 trial in patients with glioblastoma at Northwestern University.
Exicure reported fourth quarter and full year financial results for the year ended December 31, 2020 and provided an update on corporate progress.
Exicure today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.